<DOC>
	<DOCNO>NCT00637585</DOCNO>
	<brief_summary>To examine relative potency , onset action duration action fexofenadine HCl 180 mg ( ALLEGRA ) desloratadine 5 mg ( CLARINEX ) compare placebo skin wheal flare induce histamine .</brief_summary>
	<brief_title>Fexofenadine HCl 180 mg , Desloratadine 5 mg Placebo Suppression Wheal Flare Induced Histamine</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Male female subject , 12 55 year age , may participate Positive histamine skin prick test ( duplicate histamine skin prick test ) summation flare ( ΣF ) great equal 20 mm large diluent control , summation wheal ( ΣW ) great equal 6 mm large diluent control screen visit 1 All female subject must negative urine pregnancy test screen visit Female subject sexually active expect use one follow birth control method throughout study ( see Section 4.4 ) Subjects must within 15 % normal body weight height BMI le 29.9 ( base NHLBI guideline ) Subjects willing able adhere visit schedule study requirement All female subject must negative urine pregnancy test treatment visit ( Visit 2 , 4 , 6 ) . Continues meet inclusion exclusion criterion Asthma require treatment medication inhale , shortacting beta agonist Signs symptom currently active allergic disease ( seasonal allergic rhinitis , perennial allergic rhinitis , episodic allergic rhinitis ) Upper respiratory tract infection , sinusitis , asthma flulike symptom within 2 week prior visit 1 Subjects dermatographism skin condition might interfere interpretation skin test result Subjects receive immunotherapy Any excessive amount alcohol ( two drinks/day average ) Any excessive use caffeine ( six cup coffee per day equivalent ) Any use tobacco/nicotine product within 90 day visit 1 Any disease state surgery know affect gastrointestinal absorption drug Known hypersensitivity investigational product drug similar chemical property Subjects visit tan salon study Subjects need use artificial tanning product study Night variable shift worker study Pregnancy Breastfeeding History hypersensitivity study medication drug similar chemical structure Treatment H1receptor antagonist last year study entry Likelihood require treatment study period drug permit clinical study protocol ( see Section 6.2 ) Treatment investigational product last 30 day study entry No person child person directly associate administration study may participate study subject Clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease make implementation protocol interpretation study result difficult Mental condition render subject unable understand nature , scope , possible consequence study Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study Use follow drug within time indicated prior first dose visit :</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>